Browse > Article

Pharmacokinetics of Once-Daily Amikacin in Korean Adult Patients  

Kim, Hye-Kyung (Department of Pharmacy, Gangnam Severance Hospital)
Ji, Eun-Hee (College of Pharmacy, Seoul National University)
Ahn, Bo-Sook (Department of Pharmacy, Gangnam Severance Hospital)
Shin, Wan-Gyoon (College of Pharmacy, Seoul National University)
Oh, Jung-Mi (College of Pharmacy, Seoul National University)
Publication Information
Korean Journal of Clinical Pharmacy / v.21, no.3, 2011 , pp. 208-214 More about this Journal
Keywords
once-daily amikacin; pharmacokinetic parameter; creatinine clearance;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Blaser J, Donig C, Ftio R, et al., Multicenter quality control study of amikacin assay for monitoring once-daily dosing regimens. TDM 1995; 17: 133-6.
2 Raveh D, Kopyt M, Hite Y, et al., Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides. Q J Med 2002; 95: 291-7.   DOI
3 Susser Z, Raveh D, Yinnon AM. Safety of once-daily aminoglycosides in the elderly. J Am Geriatr Soc 2000;4 8: 857-9.   DOI
4 Bartal C, Danon A, Schlaeffer F, et al., Pharmacokinetic dosing aminoglycosides: A controlled trial. Am J Med 2003; 114: 194-198.   DOI   ScienceOn
5 Zaera S, Hermida J, Tutor C. Effect of analytical inaccuracy on dose adjustment for vancomycin, amikacin, and tobramycin using the abbottbase pharmacokinetic systems. TDM 2002; 24: 696-700.
6 Desoky E, Meinshausen J, Buhl K., et al., Generation of pharmacokinetic data during routine therapeutic drug monitoring: bayesian approach vs. pharmacokinetic studies. TDM 1993; 15: 281-8.
7 Ried LD, Mckenna DA, Horn JR. Effect of therapeutic drug monitoring services on the number of serum drug assays ordered for patients: A meta-analysis. TDM 1989; 11: 253-63.
8 Winston L, Benowitz N. Once-daily dosing of aminoglycosides: How much monitoring is truly required? Am J Med 2003; 114: 239-40.   DOI   ScienceOn
9 Tod M, Lortholary O, Seytre D, et al., Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults. Antimicrob Agents Ch 1998; 42: 849-56.
10 Lugo G, Castañeda-Hernández G. Amikacin bayesian forecasting in critically ill patients with sepsis and cirrhosis. TDM 1997; 19: 271-6.
11 Bacopoulou F, Markantonis SL, Pavlou E, et al., A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes. J Crit Care 2003; 18: 107-13.   DOI   ScienceOn
12 Raveh D, Kopyt M, Hite Y, et al., Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides. Q J Med 2002; 95: 291-7.   DOI
13 Beauchamp D, Labrecque G. Aminoglycoside nephrotoxicity: do time and frequency of administration matter? Current Opinion in Critical Care 2001; 7: 402-8.
14 Rougier F, Ducher M, Maurin M, et al., Aminoglycoside dosages and nephrotoxicity. Clin Pharmacokinetic 2003; 42: 493-500.   DOI   ScienceOn
15 Giamarellou H, Yiallouros K, Petrikkow G, et al., Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gramnegative infections. J Antimicro Chemoth 1991; 27: 73-9.   DOI
16 Freeman CD, Nicolau DP, Belliveau PP, et al., Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemoth 1997; 39: 677-86.   DOI   ScienceOn
17 Rougier F, Claude D, Maurin M, et al., Aminoglycoside Nephrotoxicity: Modeling, simulation, and control. Antimicrob Agents Ch 2003; 47: 1010-6.   DOI   ScienceOn
18 Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a Meta-analysis. Ann Intern Med 1996; 124: 717-25.   DOI   ScienceOn
19 Karachalios GN, Houpas P, Tziviskou E, et al., Prospective randomized study of once-daily versus twicedaily amikacin regimens in patients with systemic infections. Int J Clin Pharm Th 1998; 36: 561-4.
20 Ferriols-Lisart R, Alós-Almiñana M. Effectiveness and safety of once-daily aminoglycosides: A meta-analysis. Am J Health-Syst Pharm 1996; 53: 1141-50.
21 Staneva M, Markova B, Atanasova I, et al., Pharmacokinetic and pharmacodynamic approach for comparing two therapeutic regimens using amikacin. Antimicrob Agents Ch 1994; 38: 981-5.   DOI   ScienceOn
22 Santre C, Georges H, Jacquier JM, et al., Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily. Antimicrob Agents Ch 1995; 39: 264-7.   DOI   ScienceOn
23 Bressolle F, Gouby A, Martinez JM, et al., Population pharmacokinetics of amikacin in critically ill patients. Antimicrob Agents Ch 1996; 40: 1682-9.
24 Vanhaeverbeek M. Pharmacokinetics of once-daily amikacin in elderly patients. J Antimicrob Chemoth 1993; 31: 185-7.
25 Botha FJ, van der Bijil P, Seifart HI, et al., Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance seriously ill patients. Inten Care Med 1996; 22: 443-6.   DOI   ScienceOn
26 Nathalie B, Biatrice AL, Alain L, et al., Diurnal changes in the pharmacokinetic behavior of amikacin. TDM 2000; 22: 307-12.
27 Romano S, Fdez de Gatta MM, Calvo MV, et al., Population pharmacokinetics of amikacin in patients with haematological malignancies. J Antimicrob Chemoth 1999; 44: 235-42.   DOI
28 Gamer JS, Jarvis WR, Emori TG. DCP definitions for nosocomial infections. Am J Infect Control 1998;16:128-40.
29 Anwera PV. Pharmacokinetic evaluation of single daily dose amikacin. J Antimicro Chemoth 1991; 27 :63-71.
30 Marik PE, Havlik I, Monteagudo FS, et al., The pharmacokinetics of amikacin in critically ill adult and paediatric patients: comparison of once-versus twice dosing regimens. J Ant. Chemo 1991; 27: 81-9.